Applied Graphene Materials (LON:AGM) has signed an exclusive distribution agreement with Dichem Polymers that will give it access to the polymers and coatings markets in Greece. Dichem has a long track record of supplying high-performance chemicals to markets such as cosmetics, pharmaceuticals, the food industry, polymers and coatings, said AGM. The two companies will collaborate on the introduction of AGM’s proprietary Genable graphene dispersions technology into Greece. In a statement, Adrian Potts, AGM’s chief executive said he was delighted with the addition of Dichem to its commercial team.
Braveheart Investment Group PLC (LON:BRH), has said that that, further to its announcement on May 21, 2020, the consent of certain PhaseFocus Holdings Limited shareholders has been obtained and, therefore, completion of the acquisition of a further 22,145 ordinary shares in PhaseFocus will occur on completion of the admission to trading of a total of 700,000 new ordinary shares of 2p each in Braveheart at a price of 29p per ordinary share as non-cash consideration. Upon completion of the transaction, Braveheart will own 42.67% of the issued share capital of PhaseFocus.
Separately Braveheart also said it was notified today that Trevor Brown, its chief executive officer has acquired 972,385 ordinary shares in the group at a price of 17p per share in an off-market transaction. It noted that Brown now holds a total beneficial interest in 5,956,262 Braveheart ordinary shares, equivalent to 18.99% of the company’s voting rights.
C4X Discovery Holdings PLC (LON:C4XD) has revealed that its chief executive, Clive Dix has been appointed as a member and deputy chair of the steering board of the UK Vaccine Taskforce. The taskforce has been set up by the UK government’s chief scientific adviser, deputy chief medical officer, business secretary and health secretary to lead UK efforts to find and manufacture a coronavirus (COVID-19) vaccine. The drug discovery firm said Dix’s appointment will not impact his day-to-day role as CEO.
Tissue Regenix Group PLC (LON:TRX) has reported higher revenues for 2019 as the firm saw sales rise across all of its main business divisions. For the year ended December 31, 2019, the regenerative medicine specialist posted a 12% rise in revenues to £13.03mln and narrowed its operating loss to £7.2mln from £8.69mln in the prior year. The revenue rise was boosted by a 25% increase in sales of the company’s dCELL products in BioSurgery as well as a 5% increase in sales of its BioRinse products for orthopaedics and dentistry. The group’s joint venture, GBM-v, also saw its sales expand by 13% in the year to £2.08mln. Post-period, Tissue Regenix said revenues in the first quarter of its current year had risen 18%, despite a cyberattack on its facility in San Antonio, Texas.
Block Energy PLC (LON:BLOE), the…